DMPI DelMar Pharmaceuticals Inc.

+0.01  (+1%)
Previous Close 1.43
Open 1.49
Price To Book -1.13
Market Cap 5,519,803
Shares 3,825,227
Volume 77,446
Short Ratio
Av. Daily Volume 345,886

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to be completed around mid-2020.
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
Phase 2 enrolment to be completed around mid-2020.
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Latest News

  1. DelMar Announces Relocation of Company Headquarters to San Diego
  2. The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
  3. Delmar Pharmaceuticals Announces Termination Of Rights Offering
  4. DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
  5. Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering
  6. DelMar Pharmaceuticals Announces Closing of Financing
  7. DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
  8. DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering
  9. DelMar Pharmaceuticals Updates Key Dates of Rights Offering
  10. DelMar Pharmaceuticals, Inc. to Host Earnings Call
  11. DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
  12. DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results
  13. DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
  14. DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split
  15. DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
  16. DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
  17. DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
  18. DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results